Robert Lockwood
Family Medicine · Yukon, OKNPI 1265488829
Payments from drug & device makers
Across 2,889 payments — averaging $2986.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$5M
- Pfizer$740K
- Janssen Research & Development, LLC$720K
- Bavarian Nordic A/s$619K
- GSK$417K
- Johnson & Johnson$350K
- plus $740K from 45 others
Across 2 payments — averaging $669.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
What the payments were for
- Food & beverage$6,02698%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,626,582 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 40 | $32,227 |
| MounjaroTirzepatide | 16 | $16,793 |
| FarxigaDapagliflozin Propanediol | 12 | $6,789 |
| XareltoRivaroxaban | 11 | $6,278 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 36 | $1,188 |
| Gabapentin | 39 | $1,085 |
| Sertraline Hcl | 26 | $1,077 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $975 |
| Tamsulosin Hcl | 17 | $779 |
| Cyclobenzaprine Hcl | 43 | $605 |
| Tizanidine Hcl | 31 | $592 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $541 |
| Pregabalin | 27 | $479 |
| Tramadol Hcl | 35 | $465 |
| Celecoxib | 21 | $446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $29,224 | $32,22740 claims |
| Lilly USA, LLCMounjaro | $438 | $16,79316 claims |
| AstraZenecaFarxiga | $18,670 | $6,78912 claims |
| Johnson & JohnsonXarelto | $350,122 | $6,27811 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $1,07726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Yukon
- Kyle RicknerYukon$14.7M
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
- Richard LowranceMustang$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.